Oral administration of the GnRH antagonist acyline, in a GIPET ®-enhanced tablet form, acutely suppresses serum testosterone in normal men: Single-dose pharmacokinetics and pharmacodynamics

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 3, 2009, Pages 641-645

  Amory, John Kenneth ^a   Leonard, Thomas W ^b   Page, Stephanie T ^a   O'Toole, Edel ^b   McKenna, Michael J ^b   Bremner, William J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Merrion Pharmaceuticals   (United States)

Author keywords

FSH; LH; Pharmacodynamics; Pharmacokinetics; Prostate cancer; Testosterone

Indexed keywords

ACYLINE; CREATININE; FOLLITROPIN; GIPET; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; FOLLITROPIN BLOOD LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIVER FUNCTION TEST; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TABLET FORMULATION; TESTOSTERONE BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; TABLETS; TESTOSTERONE; TIME FACTORS; YOUNG ADULT;

EID: 67349108403     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1038-1     Document Type: Article

References (18)

1. PM Conn WF Crowley 1994 Gonadotropin-releasing hormone and its analogs Annu Rev Med 45 391 405 (Pubitemid 24158170)
2. KL Herbst 2003 Gonadotropin-releasing hormone antagonists Curr Opin Pharmacol 2003 3 660 666 (Pubitemid 37451876)
3. KL Herbst BD Anawalt JK Amory WJ Bremner 2002 Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist J Clin Endocrinol Metab 87 3215 3220 (Pubitemid 34816368)
4. KL Herbst AD Coviello ST Page JK Amory BD Anawalt WJ Bremner 2004 Acyline, a gonadotropin releasing-hormone antagonist suppresses gonadotropins and testosterone for 15 days after a single dose J Clin Endocrinol Metab 89 5959 5965 (Pubitemid 39628400)
5. KL Matthiesson JK Amory R Berger A Ugoni RI McLachlan WJ Bremner 2005 Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5-alpha-reductase inhibitor or GnRH antagonist J Clin Endocrinol Metab 90 91 97 (Pubitemid 40116639)
6. ST Page JK Amory BD Anawalt M Irwig A Brockenbrough AM Matsumoto WJ Bremner 2006 Testosterone gel combined with depomedroxyprogesterone acetate (DMPA) is an effective male hormonal contraceptive regimen but is not enhanced by the addition of the GnRH antagonist acyline J Clin Endocrinol Metab 91 4374 4380 (Pubitemid 44833412)
7. TW Leonard J Lynch MJ McKenna DJ Brayden 2006 Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET Expert Opin Drug Deliv 3 685 692 (Pubitemid 44383494)
8. RS Struthers T Chen B Campbell R Jimenez H Pan SSC Yen HP Bozigian 2006 Suppression of serum luteinizing hormone in postmenopausal women by an orally administered nonpeptide antagonist of the gonadotropin-releasing hormone receptor (NBI-42902) J Clin Endocrinol Metab 91 3903 3907 (Pubitemid 44536862)
9. SN Pavlou G Wakefield NL Schlecter J Lindner KH Souza TC Kamilaris S Donidaris JE Rivier WW Vale M Toglia 1989 Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men J Clin Endocrinol Metab 68 446 454 (Pubitemid 19052891)
10. K Erb K Junge B Pechstein E Schneider H Derendorf R Hermann 2002 Novel formulations of cetrorelix acetate in healthy men: pharmacodynamic effects and noncompartmental pharmacokinetics J Clin Pharmacol 42 995 1001 (Pubitemid 34920797)
11. SL Wong DTW Lau SA Baughman N Fotheringham D Menchaca MB Garnick 2004 Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50-75 J Clin Pharmacol 44 495 502 (Pubitemid 38509718)
12. A Reyes-Fuentes ME Chavarria A Carrera G Aguilera A Rosado E Samojlik A Iranmanesh JD Veldhuis 1996 Alterations in pulsatile luteinizing hormone and follicle-stimulating hormone secretion in idiopathic oligoasthenospermic men: assessment by deconvolution analysis-a clinical research center study J Clin Endocrinol Metab 81 524 529 (Pubitemid 26055658)
13. SH Tan AC Wolff 2008 The role of ovarian ablation in the adjuvant therapy of breast cancer Curr Oncol Rep 10 27 37
14. MR Smith 2007 Androgen deprivation therapy for prostate cancer: new concepts and concerns Curr Opin Endocrinol Diabetes Obes 14 247 254 (Pubitemid 46684481)
15. White CD, Stewart Aj, Lu ZL, Millar RP, Morgan K (2008) Antiproliferative effects of GnRH agonists: prospects and problems for cancer therapy. Neuroendocrinology 2008 (Feb 29 E pub)
16. AR Gunthert C Grundker A Olata J Lasche N Eicke G Emons 2005 Analogs of GnRH-1 and GnRH-2 inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen Eur J Endocrinol 153 613 625 (Pubitemid 41556289)
17. D Dondi C Festuccia M Piccolella M Bologna M Mott 2006 GnRH agonist and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system Oncol Rep 15 393 400
18. G Boustead SJ Edwards 2007 Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials BJU Int 99 1383 1389